228
Participants
Start Date
May 31, 2009
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
AZD1305
Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Placebo
iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Research Site, Brno
Research Site, Prague
Research Site, Znojmo
Research Site, Aalborg
Research Site, Esbjerg
Research Site, Svendborg
Research Site, Budapest
Research Site, Cegléd
Research Site, Debrecen
Research Site, Kecskemét
Research Site, Székesfehérvár
Research Site, Breda
Research Site, Deventer
Research Site, Leeuwarden
Research Site, Sneek
Research Site, Hamar
Research Site, Oslo
Research Site, Rud
Research Site, Tromsø
Research Site, Bytom
Research Site, Lubin
Research Site, Płock
Research Site, Ruda Śląska
Research Site, Torun
Research Site, Warsaw
Research Site, Martin
Research Site, Nitra
Research Site, Ružomberok
Research Site, Linköping
Research Site, Örebro
Research Site, Stockholm
Lead Sponsor
AstraZeneca
INDUSTRY